Clinic Roundup
• Coronado Biosciences Inc., of Burlington, Mass., said development partner Dr. Falk Pharma GmbH, of Freiburg, Germany, disclosed the independent data monitoring committee's recommendation to continue Falk's Phase II trial in Europe evaluating Trichuris suis ova (TSO) in Crohn's disease following an interim analysis of clinical data, blinded to Falk, of the initial 120 patients.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.